Cargando…

Phase 1, randomized, parallel-group, double-blind, placebo-controlled trial to evaluate the effects of erenumab (AMG 334) and concomitant sumatriptan on blood pressure in healthy volunteers

OBJECTIVES: The aim of this study was to assess the effects of concomitant administration of erenumab and sumatriptan on resting blood pressure, pharmacokinetics, safety, and tolerability in healthy subjects. METHODS: In this phase 1, parallel-group, one-way crossover, double-blind, placebo-controll...

Descripción completa

Detalles Bibliográficos
Autores principales: de Hoon, Jan, Van Hecken, Anne, Vandermeulen, Corinne, Herbots, Marissa, Kubo, Yumi, Lee, Ed, Eisele, Osa, Vargas, Gabriel, Gabriel, Kristin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6348461/
https://www.ncbi.nlm.nih.gov/pubmed/29783863
http://dx.doi.org/10.1177/0333102418776017
_version_ 1783390107013742592
author de Hoon, Jan
Van Hecken, Anne
Vandermeulen, Corinne
Herbots, Marissa
Kubo, Yumi
Lee, Ed
Eisele, Osa
Vargas, Gabriel
Gabriel, Kristin
author_facet de Hoon, Jan
Van Hecken, Anne
Vandermeulen, Corinne
Herbots, Marissa
Kubo, Yumi
Lee, Ed
Eisele, Osa
Vargas, Gabriel
Gabriel, Kristin
author_sort de Hoon, Jan
collection PubMed
description OBJECTIVES: The aim of this study was to assess the effects of concomitant administration of erenumab and sumatriptan on resting blood pressure, pharmacokinetics, safety, and tolerability in healthy subjects. METHODS: In this phase 1, parallel-group, one-way crossover, double-blind, placebo-controlled study, healthy adult subjects were randomized (1:2) to receive either intravenous placebo and subcutaneous sumatriptan 12 mg (i.e. two 6-mg injections separated by 1 hour) or intravenous erenumab 140 mg and subcutaneous sumatriptan 12 mg. Blood pressure was measured pre-dose and at prespecified times post-dose. The primary endpoint was individual time-weighted averages of mean arterial pressure, measured from 0 hours to 2.5 hours after the first dose of sumatriptan. Pharmacokinetic parameters for sumatriptan were evaluated by calculating geometric mean ratios (erenumab and sumatriptan/placebo and sumatriptan). Adverse events and anti-erenumab antibodies were also evaluated. RESULTS: A total of 34 subjects were randomized and included in the analysis. Least squares mean (standard error) time-weighted averages of mean arterial pressure were 87.4 (1.0) mmHg for the placebo and sumatriptan group and 87.4 (1.2) mmHg for the erenumab and sumatriptan group. Mean difference in mean arterial pressure between groups was −0.04 mmHg (90% confidence interval: −2.2, 2.1). Geometric mean ratio estimates for maximum plasma concentration of sumatriptan was 0.95 (90% confidence interval: 0.82, 1.09), area under the plasma concentration–time curve (AUC) from time 0 to 6 hours was 0.98 (90% confidence interval: 0.93, 1.03), and AUC from time 0 to infinity was 1.00 (90% confidence interval: 0.96, 1.05). No clinically relevant safety findings for co-administration of sumatriptan and erenumab were identified. CONCLUSION: Co-administration of erenumab and sumatriptan had no additional effect on resting blood pressure or on pharmacokinetics of sumatriptan. Trial registration: ClinicalTrials.gov, NCT02741310.
format Online
Article
Text
id pubmed-6348461
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-63484612019-02-15 Phase 1, randomized, parallel-group, double-blind, placebo-controlled trial to evaluate the effects of erenumab (AMG 334) and concomitant sumatriptan on blood pressure in healthy volunteers de Hoon, Jan Van Hecken, Anne Vandermeulen, Corinne Herbots, Marissa Kubo, Yumi Lee, Ed Eisele, Osa Vargas, Gabriel Gabriel, Kristin Cephalalgia Original Articles OBJECTIVES: The aim of this study was to assess the effects of concomitant administration of erenumab and sumatriptan on resting blood pressure, pharmacokinetics, safety, and tolerability in healthy subjects. METHODS: In this phase 1, parallel-group, one-way crossover, double-blind, placebo-controlled study, healthy adult subjects were randomized (1:2) to receive either intravenous placebo and subcutaneous sumatriptan 12 mg (i.e. two 6-mg injections separated by 1 hour) or intravenous erenumab 140 mg and subcutaneous sumatriptan 12 mg. Blood pressure was measured pre-dose and at prespecified times post-dose. The primary endpoint was individual time-weighted averages of mean arterial pressure, measured from 0 hours to 2.5 hours after the first dose of sumatriptan. Pharmacokinetic parameters for sumatriptan were evaluated by calculating geometric mean ratios (erenumab and sumatriptan/placebo and sumatriptan). Adverse events and anti-erenumab antibodies were also evaluated. RESULTS: A total of 34 subjects were randomized and included in the analysis. Least squares mean (standard error) time-weighted averages of mean arterial pressure were 87.4 (1.0) mmHg for the placebo and sumatriptan group and 87.4 (1.2) mmHg for the erenumab and sumatriptan group. Mean difference in mean arterial pressure between groups was −0.04 mmHg (90% confidence interval: −2.2, 2.1). Geometric mean ratio estimates for maximum plasma concentration of sumatriptan was 0.95 (90% confidence interval: 0.82, 1.09), area under the plasma concentration–time curve (AUC) from time 0 to 6 hours was 0.98 (90% confidence interval: 0.93, 1.03), and AUC from time 0 to infinity was 1.00 (90% confidence interval: 0.96, 1.05). No clinically relevant safety findings for co-administration of sumatriptan and erenumab were identified. CONCLUSION: Co-administration of erenumab and sumatriptan had no additional effect on resting blood pressure or on pharmacokinetics of sumatriptan. Trial registration: ClinicalTrials.gov, NCT02741310. SAGE Publications 2018-05-21 2019-01 /pmc/articles/PMC6348461/ /pubmed/29783863 http://dx.doi.org/10.1177/0333102418776017 Text en © International Headache Society 2018 http://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Original Articles
de Hoon, Jan
Van Hecken, Anne
Vandermeulen, Corinne
Herbots, Marissa
Kubo, Yumi
Lee, Ed
Eisele, Osa
Vargas, Gabriel
Gabriel, Kristin
Phase 1, randomized, parallel-group, double-blind, placebo-controlled trial to evaluate the effects of erenumab (AMG 334) and concomitant sumatriptan on blood pressure in healthy volunteers
title Phase 1, randomized, parallel-group, double-blind, placebo-controlled trial to evaluate the effects of erenumab (AMG 334) and concomitant sumatriptan on blood pressure in healthy volunteers
title_full Phase 1, randomized, parallel-group, double-blind, placebo-controlled trial to evaluate the effects of erenumab (AMG 334) and concomitant sumatriptan on blood pressure in healthy volunteers
title_fullStr Phase 1, randomized, parallel-group, double-blind, placebo-controlled trial to evaluate the effects of erenumab (AMG 334) and concomitant sumatriptan on blood pressure in healthy volunteers
title_full_unstemmed Phase 1, randomized, parallel-group, double-blind, placebo-controlled trial to evaluate the effects of erenumab (AMG 334) and concomitant sumatriptan on blood pressure in healthy volunteers
title_short Phase 1, randomized, parallel-group, double-blind, placebo-controlled trial to evaluate the effects of erenumab (AMG 334) and concomitant sumatriptan on blood pressure in healthy volunteers
title_sort phase 1, randomized, parallel-group, double-blind, placebo-controlled trial to evaluate the effects of erenumab (amg 334) and concomitant sumatriptan on blood pressure in healthy volunteers
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6348461/
https://www.ncbi.nlm.nih.gov/pubmed/29783863
http://dx.doi.org/10.1177/0333102418776017
work_keys_str_mv AT dehoonjan phase1randomizedparallelgroupdoubleblindplacebocontrolledtrialtoevaluatetheeffectsoferenumabamg334andconcomitantsumatriptanonbloodpressureinhealthyvolunteers
AT vanheckenanne phase1randomizedparallelgroupdoubleblindplacebocontrolledtrialtoevaluatetheeffectsoferenumabamg334andconcomitantsumatriptanonbloodpressureinhealthyvolunteers
AT vandermeulencorinne phase1randomizedparallelgroupdoubleblindplacebocontrolledtrialtoevaluatetheeffectsoferenumabamg334andconcomitantsumatriptanonbloodpressureinhealthyvolunteers
AT herbotsmarissa phase1randomizedparallelgroupdoubleblindplacebocontrolledtrialtoevaluatetheeffectsoferenumabamg334andconcomitantsumatriptanonbloodpressureinhealthyvolunteers
AT kuboyumi phase1randomizedparallelgroupdoubleblindplacebocontrolledtrialtoevaluatetheeffectsoferenumabamg334andconcomitantsumatriptanonbloodpressureinhealthyvolunteers
AT leeed phase1randomizedparallelgroupdoubleblindplacebocontrolledtrialtoevaluatetheeffectsoferenumabamg334andconcomitantsumatriptanonbloodpressureinhealthyvolunteers
AT eiseleosa phase1randomizedparallelgroupdoubleblindplacebocontrolledtrialtoevaluatetheeffectsoferenumabamg334andconcomitantsumatriptanonbloodpressureinhealthyvolunteers
AT vargasgabriel phase1randomizedparallelgroupdoubleblindplacebocontrolledtrialtoevaluatetheeffectsoferenumabamg334andconcomitantsumatriptanonbloodpressureinhealthyvolunteers
AT gabrielkristin phase1randomizedparallelgroupdoubleblindplacebocontrolledtrialtoevaluatetheeffectsoferenumabamg334andconcomitantsumatriptanonbloodpressureinhealthyvolunteers